Skip to navigation Skip to content

Diagnostic Workup


Diagnostic workup tools

Consortium of MS Centers MRI Protocol and Clinical Guidelines

New to the 2018 CMSC MRI protocol and guidelines are recommendations of when to use gadolinium based contrast agents (GBCAs). They recommend using GBCAs in the following circumstances:
  • in patients presenting with a first clinical attack (CIS) to facilitate early diagnosis
  • in patients with highly active disease
  • in a patient whose condition is declining rapidly and unexplained
  • in a patient where the diagnosis is uncertain

Gadolinium FDA drug safety communication

In 2018 the FDA Issued a Safety Communication and Safety Measures Related to a Commonly Used MRI Contrast Agent.  The FDA is evaluating the risk of brain deposits with repeated use of gadolinium-based contrast agents for MRI.


Become a Research Champion

An MS Research Revolution

Support MS Research

Understanding and ending MS can’t come fast enough – it will take all of us working together. It’s easy to be a champion for MS Research – join us and proudly let everyone know that you’re helping to lead the MS Research Revolution.

Become a Research Champion

Become a Research Champion
© 2020 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.